Study wrapper · #963
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
Editor's note
This systematic review, meta-analysis and meta-regression pools three RCTs comparing CagriSema and cagrilintide monotherapy against semaglutide. CagriSema was associated with significantly greater weight loss, while cagrilintide alone matched semaglutide but carried a higher relative risk of serious adverse events and combination therapy increased injection-site reactions and nausea. As a synthesis of randomized data on tracked peptides it is strong evidence, with both benefits and safety signals reported as associations.
Plain-language abstract
A meta-analysis of three trials with 3,545 participants found that CagriSema produced greater weight loss than semaglutide alone, while cagrilintide monotherapy achieved comparable weight loss with a higher rate of serious adverse events.